GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Prostate Cancer
Interventions
DRUG

GEMOX

Gemcitabine 1000 mg/m2 IV on day 1 every 2 weeks (fixed-dose rate 10 mg/m2/min) Oxaliplatin 100 mg/m2 IV on day 1 every 2 weeks Prednisolone 5 mg twice a day orally daily

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT01487720 - GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter